Evidence map›Paper›PMID 31905709›Full record

ArticleCells2019

Cirrhotic Human Liver Extracellular Matrix 3D Scaffolds Promote Smad-Dependent TGF-β1 Epithelial Mesenchymal Transition.

Giuseppe Mazza, Andrea Telese, Walid Al-Akkad, Luca Frenguelli, Ana Levi, Martina Marrali, Lisa Longato, Kessarin Thanapirom, Maria Giovanna Vilia, Benedetta Lombardi and 17 more

Abstract read
In one paragraph

Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Serum Proteomic Profile Based on the TGF-β Pathway Stratifies Risk of Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  6. Exploring Cirrhosis: Insights into Advances in Therapeutic Strategies.International journal of molecular sciences · 2025
    Review
  7. Proteomic analysis of liver fibrosis reveals EFEMP1 as a new modulator of focal adhesion and migration of hepatic stellate cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  8. Article
  9. Protective effects ofCytotechnology · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Hepatic inflammatory responses in liver fibrosis.Nature reviews. Gastroenterology & hepatology · 2023
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Giuseppe MazzaRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Andrea TeleseRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Walid Al-AkkadRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Luca FrenguelliRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Ana LeviRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Martina MarraliRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Lisa LongatoEngitix Ltd., London NW3 2PF, UK.
Kessarin ThanapiromRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Maria Giovanna ViliaRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Benedetta LombardiProteomics and Molecular Cell Dynamics, Centre for Nephrology, School of Life and Medical Sciences, University College London, London NW3 2PF, UK.
Claire CrowleyStem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme, UCL Institute for Child Health, Great Ormond Street Hospital, University College London, London WC1N 3JH, UK.
Mark CrawfordProteomics and Molecular Cell Dynamics, Centre for Nephrology, School of Life and Medical Sciences, University College London, London NW3 2PF, UK.
Morten A KarsdalNordic Bioscience, Biomarkers & Research, Herlev Hovedgade 205-207, 2730 Herlev, Denmark.
Diana J LeemingNordic Bioscience, Biomarkers & Research, Herlev Hovedgade 205-207, 2730 Herlev, Denmark.
Giusi MarroneRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Katrin BottcherRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Benjamin RobinsonDepartment of Bioengineering, Cellular and Molecular Biomechanics. Imperial College, London SW7 2AZ, UK.
Armando Del Rio HernandezDepartment of Bioengineering, Cellular and Molecular Biomechanics. Imperial College, London SW7 2AZ, UK.
Domenico TamburrinoRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Gabriele SpoletiniRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Massimo MalagoRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Andrew R HallRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Jasminka Godovac-ZimmermannProteomics and Molecular Cell Dynamics, Centre for Nephrology, School of Life and Medical Sciences, University College London, London NW3 2PF, UK.
Tu Vinh LuongRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Paolo De CoppiStem Cells and Regenerative Medicine Section, Developmental Biology and Cancer Programme, UCL Institute for Child Health, Great Ormond Street Hospital, University College London, London WC1N 3JH, UK.
Massimo PinzaniRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.
Krista RomboutsRegenerative Medicine & Fibrosis Group, Institute for Liver and Digestive Health, University College London (UCL), London NW3 2PF, UK.

Funding

European Research Council A.D.R.H. 282051UCL NIHR Biomedical Research Centre K.R. BRC648 and M.P.- G.M. BRC293
6 · The paper itself

Abstract

An altered liver microenvironment characterized by a dysregulated extracellular matrix (ECM) supports the development and progression of hepatocellular carcinoma (HCC). The development of experimental platforms able to reproduce these physio-pathological conditions is essential in order to identify and validate new therapeutic targets for HCC. The aim of this work was to validate a new in vitro model based on engineering three-dimensional (3D) healthy and cirrhotic human liver scaffolds with HCC cells recreating the micro-environmental features favoring HCC. Healthy and cirrhotic human livers ECM scaffolds were developed using a high shear stress oscillation-decellularization procedure. The scaffolds bio-physical/bio-chemical properties were analyzed by qualitative and quantitative approaches. Cirrhotic 3D scaffolds were characterized by biomechanical properties and microarchitecture typical of the native cirrhotic tissue. Proteomic analysis was employed on decellularized 3D scaffolds and showed specific enriched proteins in cirrhotic ECM in comparison to healthy ECM proteins. Cell repopulation of cirrhotic scaffolds highlighted a unique up-regulation in genes related to epithelial to mesenchymal transition (EMT) and TGFβ signaling. This was also supported by the presence and release of higher concentration of endogenous TGFβ1 in cirrhotic scaffolds in comparison to healthy scaffolds. Fibronectin secretion was significantly upregulated in cells grown in cirrhotic scaffolds in comparison to cells engrafted in healthy scaffolds. TGFβ1 induced the phosphorylation of canonical proteins Smad2/3, which was ECM scaffold-dependent. Important, TGFβ1-induced phosphorylation of Smad2/3 was significantly reduced and ECM scaffold-independent when pre/simultaneously treated with the TGFβ-R1 kinase inhibitor Galunisertib. In conclusion, the inherent features of cirrhotic human liver ECM micro-environment were dissected and characterized for the first time as key pro-carcinogenic components in HCC development.

Indexed as

Epithelial-Mesenchymal TransitionTissue ScaffoldsBioengineeringCarcinoma, HepatocellularCollagenExtracellular MatrixHumansImmunohistochemistryLiver CirrhosisPhosphorylationProteomicsSignal TransductionSmad2 ProteinSmad3 ProteinSmad ProteinsTransforming Growth Factor beta1CollagenSmad2 ProteinSMAD2 protein, humanSmad3 ProteinSMAD3 protein, humanSmad ProteinsTransforming Growth Factor beta13D ECM scaffolds3-dimensional (3D) platformdecellularized extracellular matrix (dECM)decellularized human liverhepatocellular carcinoma cellshepatocellular carcinoma (HCC)proteomicstissue engineeringTransforming growth factor beta1 (TGF-β1)tumor microenvironment (TME)

Identifiers

PMID31905709
PMCPMC7017194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.